New York, Jan 11, 2026, 08:51 (EST) — Market closed.
- OLMA shares ended Friday sharply higher after a volatile stretch
- CEO set to speak at the J.P. Morgan Healthcare Conference on Jan. 13
- Recent analyst notes put near-term “catalysts” back in focus
Olema Pharmaceuticals Inc shares closed up 9.8% on Friday at $28.08, with about 2.5 million shares changing hands, as investors headed into a catalyst-heavy week for the cancer drug developer. (The Wall Street Journal)
U.S. markets reopen on Monday, and Olema is the kind of stock that can gap on a single slide deck. Conference remarks and fresh sell-side research tend to matter more than broad market tape for early-stage biotechs, at least for a day or two.
Olema said CEO Sean P. Bohen will present at the J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 13 at 11:15 a.m. PT, with a webcast posted on its investor site. The company is advancing palazestrant (OP-1250), an oral drug in two Phase 3 trials; it is designed to block and break down the estrogen receptor — a common driver in breast cancer — and it is also developing OP-3136, an early-stage KAT6 inhibitor. (Barchart)
Citi analyst Yigal Nochomovitz kept a Buy rating and a $60 price target while adding an “upside 90-day catalyst watch” on the shares, according to TheFly. On Wall Street, that kind of label is shorthand for “we think an event in the next few months can move the stock,” whether up or down. (TipRanks)
UBS initiated coverage with a Buy rating and a $45 price target, highlighting Olema’s late-stage program in a class of endocrine therapies aimed at metastatic breast cancer, Investing.com reported. UBS also pointed to multiple potential catalysts in 2026. (Investing)
Piper Sandler also started coverage this week with an Overweight rating and a $40 target, saying palazestrant could become the next “backbone endocrine therapy” in a large segment of breast cancer treatment. The firm cited competitor data from Roche late last year as helping revive interest in oral estrogen-receptor drugs, according to Investing.com. (Investing)
Across seven analyst reports tracked by Stock Analysis, Olema carries a “Strong Buy” consensus with an average price target of about $41.14, versus Friday’s close, with targets running from $20 to $60. (StockAnalysis)
The stock’s moves have also come with financing in the background. Olema raised about $218.5 million in gross proceeds in November, selling 11.5 million shares at $19 apiece in an underwritten offering, the company said at the time. (Stock Titan)
But the setup cuts both ways. Olema has no approved products, and late-stage trials can fail outright or take longer than expected; even a conference appearance can disappoint if it brings little new on timelines, trial design, or cash runway.
For the week ahead, traders will watch whether Friday’s rebound holds into Monday’s open and whether any new analyst notes land before management takes the stage. The next hard catalyst is Bohen’s scheduled J.P. Morgan conference slot on Tuesday, Jan. 13 (2:15 p.m. ET), when investors will look for any new detail on palazestrant’s Phase 3 path and what comes after.
